Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy

Clinical Ophthalmology

Volumn 6, Issue 1, 2012, Pages 1259-1269

  Singh, Rishi ^a   Alpern, Louis ^b   Jaffe, Glenn J ^c   Lehmann, Robert P ^d   Lim, John ^e   Reiser, Harvey J ^f   Sall, Kenneth ^g   Walters, Thomas ^h   Sager, Dana ⁱ  

^a LERNER RESEARCH INSTITUTE   (United States)

^b The Cataract   (United States)

^c DUKE UNIVERSITY EYE CENTER   (United States)

^d Lehmann Eye Center   (United States)

^e Houston Eye Associates   (United States)

^f Sall Research Medical Center ^*

^g Texan Eye   (United States)

^h ALCON RESEARCH LTD   (United States)

ⁱ ALCON RESEARCH LTD   (United States)

Author keywords

Cataract extraction; Diabetes; Macular edema; Nonsteroidal anti inflammatory drug; Ocular surgery; Retinopathy; Topical

Indexed keywords

NEPAFENAC; PLACEBO;

ADULT; AGED; ARTICLE; CATARACT EXTRACTION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORNEA EROSION; DIABETIC RETINOPATHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PANCREATITIS; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA EDEMA; RETINA MACULA LUTEA; RETINA MACULA LUTEA THICKNESS; RETINA MACULA LUTEA VOLUME; RISK BENEFIT ANALYSIS; TREATMENT DURATION; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

EID: 84930485850     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S31902     Document Type: Article

References (37)

1. Tranos PG, Wickremasinghe SS, Stangos NT, Topouzis T, Tsinopoulos I, Pavesio CE. Macular edema. Surv Ophthalmol. 2004;49:470-490.
2. Gallemore RP. NSAIDs in treatment of retinal disorders. Rev Ophth. 2006;13:81-88.
3. Powe NR, Schein OD, Gieser SC, et al. Synthesis of the literature on visual acuity and complications following cataract extraction with intraocular lens implantation. Cataract Patient Outcome Research Team. Arch Ophthalmol. 1994;112:239-252.
4. Ursell PG, Spalton DJ, Whitcup SM, Nussenblatt RB. Cystoid macular edema after phacoemulsification: relationship to blood-aqueous barrier damage and visual acuity. J Cataract Refract Surg. 1999;25: 1492-1497.
5. Hayashi K, Igarashi C, Hirata A, Hayashi H. Changes in diabetic macular oedema after phacoemulsification surgery. Eye (Lond). 2009;23: 389-396.
6. Degenring RF, Vey S, Kamppeter B, Budde WM, Jonas JB, Sauder G. Effect of uncomplicated phacoemulsification on the central retina in diabetic and non-diabetic subjects. Graefes Arch Clin Exp Ophthalmol. 2007;245:18-23.
7. Rossetti L, Autelitano A. Cystoid macular edema following cataract surgery. Curr Opin Ophthalmol. 2000;11:65-72.
8. Johnson MW. Etiology and treatment of macular edema. Am J Ophthalmol. 2009;147:11-21.
9. Dowler JG, Sehmi KS, Hykin PG, Hamilton AM. The natural history of macular edema after cataract surgery in diabetes. Ophthalmology. 1999;106:663-668.
10. Pollack A, Leiba H, Bukelman A, Oliver M. Cystoid macular oedema following cataract extraction in patients with diabetes. Br J Ophthalmol. 1992;76:221-224.
11. Pollack A, Leiba H, Bukelman A, Abrahami S, Oliver M. The course of diabetic retinopathy following cataract surgery in eyes previously treated by laser photocoagulation. Br J Ophthalmol. 1992;76:228-231.
12. Krepler K, Biowski R, Schrey S, Jandrasits K, Wedrich A. Cataract surgery in patients with diabetic retinopathy: visual outcome, progression of diabetic retinopathy, and incidence of diabetic macular oedema. Graefes Arch Clin Exp Ophthalmol. 2002;240:735-738.
13. Miyake K, Ibaraki N. Prostaglandins and cystoid macular edema. Surv Ophthalmol. 2002;47 Suppl 1:S203-S218.
14. Flach AJ. The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc. 1998;96:557-634.
15. O'Brien TP. Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care. Curr Med Res Opin. 2005;21: 1131-1137.
16. Rossetti L, Chaudhuri J, Dickersin K. Medical prophylaxis and treatment of cystoid macular edema after cataract surgery. The results of a meta-analysis. Ophthalmology. 1998;105:397-405.
17. Henderson BA, Kim JY, Ament CS, Ferrufino-Ponce ZK, Grabowska A, Cremers SL. Clinical pseudophakic cystoid macular edema. Risk factors for development and duration after treatment. J Cataract Refract Surg. 2007;33:1550-1558.
18. Gaynes BI, Onyekwuluje A. Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension. Clin Ophthalmol. 2008;2:355-368.
19. Ke TL, Graff G, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation. 2000;24:371-384.
20. Lane SS. Nepafenac: a unique nonsteroidal prodrug. Int Ophthalmol Clin. 2006;46:13-20.
21. Kapin MA, Yanni JM, Brady MT, et al. Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac. Inflammation. 2003;27:281-291.
22. Wilkinson CP, Ferris FL 3rd, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110:1677-1682.
23. Kim SJ, Belair ML, Bressler NM, et al. A method of reporting macular edema after cataract surgery using optical coherence tomography. Retina. 2008;28:870-876.
24. Kim SJ, Equi R, Bressler NM. Analysis of macular edema after cataract surgery in patients with diabetes using optical coherence tomography. Ophthalmology. 2007;114:881-889.
25. Hee MR, Puliafito CA, Duker JS, et al. Topography of diabetic macular edema with optical coherence tomography. Ophthalmology. 1998;105: 360-370.
26. Hee MR, Puliafito CA, Wong C, et al. Quantitative assessment of macular edema with optical coherence tomography. Arch Ophthalmol. 1995;113:1019-1029.
27. Goebel W, Kretzchmar-Gross T. Retinal thickness in diabetic retinopathy: a study using optical coherence tomography (OCT). Retina. 2002;22:759-767.
28. Goebel W, Franke R. Retinal thickness in diabetic retinopathy: comparison of optical coherence tomography, the retinal thickness analyzer, and fundus photography. Retina. 2006;26:49-57.
29. Campbell RJ, Coupland SG, Buhrmann RR, Kertes PJ. Optimal optical coherence tomography-based measures in the diagnosis of clinically significant macular edema: retinal volume vs foveal thickness. Arch Ophthalmol. 2007;125:619-623.
30. Bressler NM, Edwards AR, Antoszyk AN, et al. Retinal thickness on Stratus optical coherence tomography in people with diabetes and minimal or no diabetic retinopathy. Am J Ophthalmol. 2008;145:894-901.
31. Wolf EJ, Braunstein A, Shih C, Braunstein RE. Incidence of visually significant pseudophakic macular edema after uneventful phacoemulsification in patients treated with nepafenac. J Cataract Refract Surg. 2007;33:1546-1549.
32. Hariprasad SM, Akduman L, Clever JA, Ober M, Recchia FM, Mieler WF. Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%. Clin Ophthalmol. 2009;3: 147-154.
33. Hariprasad SM, Callanan D, Gainey S, He YG, Warren K. Cystoid and diabetic macular edema treated with nepafenac 0.1%. J Ocul Pharmacol Ther. 2007;23:585-590.
34. Callanan D, Williams P. Topical nepafenac in the treatment of diabetic macular edema. Clin Ophthalmol. 2008;2:689-692.
35. Krzystolik MG, Strauber SF, Aiello LP, et al; Diabetic Retinopathy Clinical Research Network. Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. Ophthalmology. 2007;114:1520-1525.
36. Nevanac® (full prescribing information). Fort Worth, TX: Alcon Laboratories Inc; 2008.
37. Heier JS, Topping TM, Baumann W, Dirks MS, Chern S. Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology. 2000;107:2034-2038.